Last reviewed · How we verify

ALX1-11 (drug) — Competitive Intelligence Brief

ALX1-11 (drug) (ALX1-11 (drug)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Wnt signaling inhibitor (monoclonal antibody). Area: Oncology.

phase 3 Wnt signaling inhibitor (monoclonal antibody) Wnt ligands Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ALX1-11 (drug) (ALX1-11 (drug)) — Shire. ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALX1-11 (drug) TARGET ALX1-11 (drug) Shire phase 3 Wnt signaling inhibitor (monoclonal antibody) Wnt ligands

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Wnt signaling inhibitor (monoclonal antibody) class)

  1. Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALX1-11 (drug) — Competitive Intelligence Brief. https://druglandscape.com/ci/alx1-11-drug. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: